TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17350525
Drug: Levobupivacaine 0.25%
Normalized name: levobupivacaine 0.25% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25% (19-mL bolus) followed by levobupivacaine 0.1% infusion
Study: 17350525
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 microg (19-mL bolus) followed by levobupivacaine 0.05% with fentanyl 4 microg/mL infusion
Study: 17350525
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 microg (19-mL bolus) followed by levobupivacaine 0.05% with clonidine 3 microg/mL infusion
Study: 11929640
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives with 20 microg estrogen
Study: 11929640
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives with 50 microg estrogen
Study: 11229219
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (660 mg) for 6 weeks (Group‐‐IIB)
Study: 1091138
Drug: Complete dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete dietary supplement consisting of a beef serum hydrolysate, a glucose polymer, and medium‐chain triglycerides
Study: 1091138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (patients who did not receive the supplement)
Study: 24667751
Drug: Glucose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (200 kcal/250 ml)
Study: 24667751
Drug: Sucrose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (200 kcal/250 ml)
Study: 24667751
Drug: High-fructose corn
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose corn syrup (HFCS) (200 kcal/250 ml)
Study: 24667751
Drug: HFCS (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFCS (200 kcal/250 ml)
Study: 9164415
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (200 mg every 8 hours, 300 mg every 8 hours, 400 mg every 8 hours)
Study: 9164415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (300 mg every 8 hours)
Study: 9164415
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (all doses)
Study: 2885638
Drug: Marrow depleted
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD4‐CD5‐CD8, group B)
Study: 2885638
Drug: Marrow depleted
Normalized name: Sus scrofa bone marrow preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD2‐CD5‐CD7, group C)
Study: 29412335
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy (20 weekly sessions, 90 min/session)
Study: 9817625
Drug: Citalopram (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-60 mg/day)
Study: 8507759
Drug: Monotherapy (single-agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (single-agent therapy)
Study: 3324441
Drug: Nitrofurantoin or
Normalized name: nitrofurantoin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin or another appropriate antibiotic
Study: 27764102
Drug: Seasonal Malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) administered once per month from September to November.
Study: 22956016
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.525% ropivacaine
Study: 22956016
Drug: Local wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound infiltration (LWI) with 20 mL of 0.525% ropivacaine
Study: 22956016
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (Control group)
Study: 15728422
Drug: Moderately intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately intensive pool exercise therapy (twice a week for 12 weeks)
Study: 11322867
Drug: Nesiritide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (0.2 microgram/kg bolus followed by 0.01 microgram/kg/min continuous infusion)
Study: 9675835
Drug: Disposable gastroscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disposable gastroscope (G-F100)
Study: 8002639
Drug: KW-2307 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 at 15 mg/m2
Study: 8002639
Drug: KW-2307 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 at 20 mg/m2
Study: 8002639
Drug: KW-2307 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 at 20 mg/m2 or higher doses
Study: 8002639
Drug: KW-2307 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 at 25 mg/m2
Study: 8002639
Drug: KW-2307 combined
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 combined with cisplatin (CDDP) at 80 mg/m2
Study: 818046
Drug: Intravenous Ara
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ara A
Study: 818046
Drug: Topical antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antiviral agents (IDU)
Study: 28222801
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 6 × 10^6 hADSCs per 3 ml suspended in phosphate buffer saline
Study: 28222801
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 3 ml phosphate buffer saline (placebo)
Study: 17314444
Drug: Topical garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical garlic gel with betamethasone cream 0.1%
Study: 17314444
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with betamethasone cream 0.1%
Study: 15153582
Drug: Randomized controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized controlled trials in podiatric medicine
Study: 11161545
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (12 U/dose) for 5 h
Study: 11161545
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (12 U/dose) for 5 days
Study: 3056498
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 1 mg (group A)
Study: 3056498
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 0.5 mg (group B)
Study: 3056498
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 5 mg (group C)
Study: 3056498
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 2.5 mg (group D)
Study: 28668855
Drug: Acetium® lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetium® lozenge (slow-release L-Cysteine)
Study: 26964163
Drug: Hooking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hooking therapy followed by safflower injection, once every 6 to 7 days, under local anesthesia. If efficacy was not satisfactory, a second treatment was given.
Study: 26964163
Drug: Safflower injection
Normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower injection applied to three points of lumbar region, once a day for 2 sessions (7 treatments per session).
Study: 16381068
Drug: Diazepam (0.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.19 mg/kg oral)
Study: 11479462
Drug: Reduced-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose recombinant tPA (8 mg bolus followed by 42 mg infusion)
Study: 11479462
Drug: Urokinase (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (1.5 million units as a 30-minute infusion)
Study: 11479462
Drug: Reduced-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose recombinant tPA
Study: 9725479
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (25 mg)
Study: 10805057
Drug: Ibuprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200 mg)
Study: 9725479
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (25 mg) and Ibuprofen (200 mg) in association
Study: 2686494
Drug: labetalol, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol, 2 mg/min to a maximum of 300 mg
Study: 28159420
Drug: Postdischarge mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge mechanical compression device (MCD) therapy
Study: 28159420
Drug: Inpatient mechanical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient mechanical compression device (MCD) therapy
Study: 21195076
Drug: PCV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV vaccine
Study: 21195076
Drug: DPTaP-Hib vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPTaP-Hib vaccine
Study: 19943711
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac solution (40 drops four times daily)
Study: 19943711
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac solution (50 drops three times daily)
Study: 15477437
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac solution
Study: 17374331
Drug: PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA therapy
Study: 26501236
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid therapy
Study: 15166685
Drug: Lorazepam, 0.5-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam, 0.5-1.0 mg orally at bedtime for 7 days
Study: 15166685
Drug: Zopiclone, 3.75-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone, 3.75-7.5 mg orally at bedtime for 7 days
Study: 11248744
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg per day rhGH administered subcutaneously at 2200 h for four days
Study: 9303394
Drug: Foscarnet cream
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Foscarnet cream
Study: 8322650
Drug: 3-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-minute infusion of adenosine (140 micrograms/kg/min)
Study: 8322650
Drug: 6-minute infusion
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-minute infusion of adenosine (140 micrograms/kg/min)
Study: 8322650
Drug: Both 3-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 3-minute and 6-minute infusions of adenosine
Study: 3505706
Drug: Behaviorally oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally oriented group therapy (4 months)
Study: 24886906
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant treatment (Curosurf®)
Study: 24886906
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant treatment (Curosurf®)
Study: 15752382
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg as a sugar-coated tablet (SCT) after fasting
Study: 15752382
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg as a sugar-coated tablet (SCT) after food
Study: 15752382
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg as a suspension after fasting
Study: 11772328
Drug: Ileal‐release preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileal‐release preparation of budesonide
Study: 10479170
Drug: PVL nadir
Normalized name: NAIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVL nadir >500 copies/mL
Study: 15174779
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg of elemental zinc daily)
Study: 1618246
Drug: 4.4 ml
Normalized name: APONVIE 32 MG in 4.4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 ml of 2% lignocaine with 1:80,000 adrenaline
Study: 1618246
Drug: 3% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% prilocaine with 0.03 IU.ml‐1 felypressin
Study: 6367098
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg plus chlorthalidone 25 mg (Tenoretic)
Study: 6367098
Drug: Sotalol 320
Normalized name: sotalol 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 320 mg plus hydrochlorothiazide 50 mg (Sotazide)
Study: 28779419
Drug: Budesonide 2
Normalized name: budesonide 2 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 2 mg/25 ml foam
Study: 24731008
Drug: Low-dose fructose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fructose infusion
Study: 19889010
Drug: Fractional laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional laser treatment (1,540-nm erbium glass laser)
Study: 18418976
Drug: Yishen Tiaojing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Tiaojing Recipe (YSTJR) plus TP 20 mg three times a day
Study: 18418976
Drug: TP 20
Normalized name: 5-HTP 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP 20 mg three times a day (Control)
Study: 10380745
Drug: Bupivacaine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2.5 mg/ml) + epinephrine (5 microg/ml)
Study: 10380745
Drug: Epinephrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (5 microg/ml) + saline (9 mg/ml)
Study: 10380745
Drug: Saline (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (9 mg/ml) only
Study: 9083303
Drug: Dilute vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilute vasopressin solution (0.05 U/mL)
Study: 1998274
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 or 40 mg once or twice daily
Study: 31964335
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation of ferrous sulfate between 80 mg and 160 mg.
Study: 30337921
Drug: HFA-134a-beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-134a-beclomethasone dipropionate (HFA-BDP) metered-dose inhaler (MDI) ETN (n = 11)
Study: 30337921
Drug: HFA-134a-beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA-134a-beclomethasone dipropionate (HFA-BDP) metered-dose inhaler (MDI) ETN
Study: 27494176
Drug: GTE confection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTE confection (1 g of green tea extract)
Study: 24864465
Drug: Intravenous meldonium
Normalized name: meldonium
DrugBank: Meldonium (DB13723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meldonium (idrinol) 1000 mg/day for 10-14 days
Study: 24864465
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy of coronary heart disease (Control Group)
Study: 22439290
Drug: Problem-solving Treatment-OcOccupational
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving Treatment-OcOccupational Therapy (PST-OT)
Study: 19006186
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (on‐medication dyskinesia)
Study: 12066244
Drug: 240 g
Normalized name: aspirin 15.6 GM (240 grains) Oral Bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 g of oral barium tracer
Study: 12066244
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of oral barium tracer
Study: 12066244
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of oral barium tracer
Study: 10434165
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 mg kg‐1
Study: 10434165
Drug: Dexamethasone 150
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 150 mg kg‐1
Study: 10434165
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 mg kg‐1 plus Dexamethasone 150 mg kg‐1
Study: 1721881
Drug: 3% polidocanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% polidocanol injection
Study: 27537530
Drug: Outpatient management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient management with oral rivaroxaban 15 mg twice daily for 21 days followed by 20 mg once daily for 90 days
Study: 24240351
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg body weight of caffeine dissolved in 200 mL of water
Study: 24240351
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of water (placebo)
Study: 17234502
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 36) received weekly packets of fruits and vegetables, asked to consume >or=200 g of vegetables and two pieces of fruit daily for 1 month.
Study: 15024533
Drug: Psychotropic medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotropic medicines use in the two least-educated groups
Study: 15024533
Drug: Psychotropic medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotropic medicines use in the two highest educated groups
Study: 15024533
Drug: Overall patterns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall patterns of psychotropic medicine use
Study: 11779909
Drug: Standard modalities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard modalities of treatment (physiotherapy, occupational and speech therapy, skilled medical and nursing care)
Study: 7652635
Drug: Ketanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (10 mg IV)
Study: 7652635
Drug: Hydralazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (5 mg IV)
Study: 2650942
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg per os
Study: 3072223
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg 3 times daily
Study: 389513
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg 3 times daily + beta-blocker
Study: 28182471
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation program using computer software (CogPack; Japanese version), administered twice a week for 12 weeks, including a weekly group session.
Study: 24276103
Drug: Intravenous piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piracetam
Study: 24276103
Drug: Intravenous dimenhydrinate
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dimenhydrinate
Study: 21159432
Drug: Pain assessment
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain assessment using the pain subscale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C‐30
Study: 19681256
Drug: 5.9% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.9% hydrogen peroxide paint‐on gel (Colgate Simply White)
Study: 15478912
Drug: Daclizumab/MMF/Steroids (Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab/MMF/Steroids (Tacrolimus started when creatinine dropped below 350 micromol/l)
Study: 15478912
Drug: Tacrolimus/MMF/Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus/MMF/Steroids
Study: 11675838
Drug: Heparin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 1,000 units/kg
Study: 11675838
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 0.2 mL/kg (Control)
Study: 9389779
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram gel containing 1 mg oestradiol for 3 months plus 20 mg oral MPA during the last 14 days
Study: 9389779
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g gel containing 2 mg oestradiol for 21 days plus 10 mg oral MPA during the last 14 days
Study: 9389779
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate tablets for 3 weeks plus 10 mg oral MPA during the last 10 days
Study: 7701040
Drug: Buprenorphine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8 mg sublingual, max 16 mg), average dose 11.2 mg